- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04828252
Low Level Laser Intervention for Individuals With Knee Osteoarthritis
June 21, 2021 updated by: National Cheng-Kung University Hospital
The Effects of Low Level Laser Intervention on Muscular Strength for Individuals With Knee Osteoarthritis
The purpose of this study was to investigate the intervention effects of low level laser for knee OA group
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
56
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Tainan, Taiwan, 701
- Department of Physical Therapy, National Cheng-Kung University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- The severity of osteoarthritis was defined by the Kellgren-Lawrence system as grade 2 - grade 3
Exclusion Criteria:
- Uncontrolled hypertension
- Malignant tumor
- Skin cancer
- Pregnant
- Dysesthesia
- Pacemaker inplement
- Cognitive problem
- Fall record within 6 months
- Dysfunction of blood coagulation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: 808nm
The wavelength of this experimental group was 808nm, total power: 3.6W, 15 minutes a session, 3 times a week for 8 weeks
|
The intervention protocol includes 2 wavelength as the experimental group, each of the were 808nm, 660nm, and 1 placebo intervention which output total power is only 0.0072W.
|
|
Active Comparator: 660nm
The wavelength of this experimental group was 660nm, total power: 3.6W, 15 minutes a session, 3 times a week for 8 weeks
|
The intervention protocol includes 2 wavelength as the experimental group, each of the were 808nm, 660nm, and 1 placebo intervention which output total power is only 0.0072W.
|
|
Placebo Comparator: Control
The wavelength of control group, total power: 0.0072W, 15 minutes a session, 3 times a week for 8 weeks
|
The intervention protocol includes 2 wavelength as the experimental group, each of the were 808nm, 660nm, and 1 placebo intervention which output total power is only 0.0072W.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes of muscular strength of thigh measured by handheld dynamometer
Time Frame: Baseline and after treatment, 8 weeks intervention
|
Muscular strength of the knee extensor and flexor on both sides and will be normalized by the body weight of participants' (lb/kg)
|
Baseline and after treatment, 8 weeks intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes of walking speed measured by the stop watch
Time Frame: Baseline and after treatment, 8 weeks intervention
|
40-m walk test, participants are instructed to walk as fast as they could, investigator records the time they spend.
(seconds)
|
Baseline and after treatment, 8 weeks intervention
|
|
Changes of stair climbing ability measured by the stop watch
Time Frame: Baseline and after treatment, 8 weeks intervention
|
stair climbing test, participants are instructed to climb stairs with a total height of 180 cm as fast as they could, investigator records the time they spend.
(seconds)
|
Baseline and after treatment, 8 weeks intervention
|
|
Changes of chair stand ability, the stop watch will be used to measure time and investigators count the time that participants complete
Time Frame: Baseline and after treatment, 8 weeks intervention
|
sit-to-stand test, participants are instructed to repeat chair stand movement as fast as they could, investigator records the times they complete.
(times)
|
Baseline and after treatment, 8 weeks intervention
|
|
Changes of dynamic balance ability measured by the stop watch
Time Frame: Baseline and after treatment, 8 weeks intervention
|
timed UP&Go test, participants are instructed to stand up from a chair and walk as fast as they could for 3 meters and back to the chair, investigator records the time they spend.
(seconds)
|
Baseline and after treatment, 8 weeks intervention
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes of joint range of motion measured by the goniometer
Time Frame: Baseline and after treatment, 8 weeks intervention
|
Joint range of motion of the hip flexion, internal and external rotation, knee flexion, extension on both sides(degrees)
|
Baseline and after treatment, 8 weeks intervention
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Chair: Cheng-Feng Lin, Ph.D, Department of Physical Therapy, National Cheng-Kung University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 9, 2020
Primary Completion (Actual)
June 4, 2021
Study Completion (Actual)
June 4, 2021
Study Registration Dates
First Submitted
February 3, 2021
First Submitted That Met QC Criteria
March 31, 2021
First Posted (Actual)
April 2, 2021
Study Record Updates
Last Update Posted (Actual)
June 22, 2021
Last Update Submitted That Met QC Criteria
June 21, 2021
Last Verified
February 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- A-ER-109-187
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.